Moreover, ongoing trials are exploring combinations with other immune checkpoint inhibitors, such as CTLA-4 inhibitors, to further enhance the anti-tumor immune response and overcome resistance mechanisms in tumors that evade immune detection. The gene discussed is CTLA4; the disease is neoplasm.